TORONTO, March 27, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that the Company’s first-in-human results for lead asset, RE104, have been accepted for a poster…


Previous articleNuminus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program
Next articleSilo Pharma Announces filing of Patent for Treatment of Fibromyalgia